AI Is Clearing Phase I. That's the Wrong Finish Line.

AI-designed drug candidates are clearing Phase I clinical trials at unprecedented rates, but this has not translated into improved success in Phase II, which tests actual disease impact and remains the major bottleneck due to biological mechanism validation. The industry overemphasizes molecule generation and underinvests in understanding mechanisms and learning from failed trials, limiting AI's effectiveness in advancing new therapies.

This Wire brief sits within Fusion42's coverage of Biotech.